Slides
Page 1
Corporate Presentation November 2025
Page 2
This presentation contains forward-looking statements. These statements may be identified by the use of words such as, but not limited to, “anticipate,” “believe,” “become,” “continue,” “could,” “design,” “estimate,” “expect,” “intend,” “may,” “might,” “on track,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or other similar terms or expressions that concern our expectations, plans and intentions. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations, and assumptions. Forward-looking statements include, without limitation, statements regarding: preclinical development, clinical development, and anticipated commercialization of Viridian’s product candidates veligrotug, VRDN-003, VRDN- 006, and VRDN-008, including Viridian's view that the THRIVE and THRIVE-2 data provides support for ongoing VRDN-003 development; anticipated start dates of studies; anticipated data results and timing of their disclosure, including the anticipated VRDN-003 topline data from the REVEAL-1 and REVEAL-2 trials and VRDN-008 healthy volunteer clinical data; Viridian’s expectations regarding the anticipated timing or likelihood of regulatory submissions and approvals, including the anticipated approval of the BLA for veligrotug, BLA submission for VRDN-003, MAA submission for veligrotug, and IND submission for VRDN-008; the impact of Breakthrough Therapy Designation; the impact of Priority Review, including the potential commercial launch of veligrotug in mid-2026, if approved; clinical trial designs, including the REVEAL-1 and REVEAL-2 global phase 3 clinical trials for VRDN-003; the potential utility, efficacy, potency, safety, clinical benefits, clinical response, convenience and number of indications of veligrotug, VRDN-003, VRDN-006, and VRDN-008, including Viridian’s view of the strength of the THRIVE durability data and veligrotug’s robust clinical profile; Viridian’s expectations regarding the potential commercialization of veligrotug and VRDN-003, if approved, including plans to launch VRDN-003 with a low-volume autoinjector; Viridian’s ability to receive milestone payments and receive royalties on the commercial sale of our product candidates, if approved, pursuant to the license agreement with Kissei; Viridian’s ability to receive milestone payments pursuant to the royalty agreement with DRI; the potential for veligrotug and VRDN-003 to transform the treatment for TED; the potential for veligrotug to be the IV treatment-of-choice for active and chronic TED; potential market sizes and market opportunities for Viridian’s product candidates, including Viridian’s belief that veligrotug is well-positioned to become a leading product in the TED market; and Viridian’s product candidates potentially being best-in-class. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to: potential utility, efficacy, potency, safety, clinical benefits, clinical response, and convenience of Viridian’s product candidates; that results or data from completed or ongoing clinical trials may not be representative of the results of ongoing or future clinical trials; that preliminary data may not be representative of final data; the timing, progress, and plans for our ongoing or future research, preclinical and clinical development programs; changes to trial protocols for ongoing or new clinical trials; expectations and changes regarding the timing for regulatory filings; regulatory interactions; expectations and changes regarding the timing for enrollment and data; uncertainty and potential delays related to clinical drug development; the duration and impact of regulatory delays in our clinical programs, including as a result of a prolonged government shutdown; the timing of and our ability to obtain and maintain regulatory approvals for our therapeutic candidates, including as a result of a prolonged government shutdown; manufacturing risks; competition from other therapies or products; estimates of market size; other matters that could affect the sufficiency of existing cash, cash equivalents, and short-term investments to fund operations; our future operating results and financial performance; Viridian’s intellectual property position; the timing of preclinical and clinical trial activities and reporting results from the same; and those risks described from time to time under the caption “Risk Factors” in our filings with the Securities and Exchange Commission (SEC), including those described in our most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q, as applicable, and supplemented from time to time by our Current Reports on Form 8-K. The forward-looking statements in this presentation represent our views as of the date of this presentation. Neither we, nor our affiliates, advisors, or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this presentation. This presentation also contains estimates and other statistical data made by independent parties and by us relating to marketsize and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. Trademarks used herein are the property of their respective owners. 2 Cautionary note regarding forward-looking statements
Page 3
First-generation product establishes significant opportunity for next-generation strategy Identify market opportunities with clear remaining unmet need Determine key areas of potential product differentiation Engineer potential best-in-class antibodies and therapeutic proteins Rapidly advance programs to patients 3 Viridian is building upon proven first market entrants to develop differentiated next-generation products
Page 4
DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 STATUS Thyroid Eye Disease (anti–IGF-1R) Portfolio Veligrotug Intravenous VRDN-003 Subcutaneous FcRn- Targeting Autoimmune Portfolio VRDN-006 FcRn-targeting Fc fragment VRDN-008 Bispecific, extended half-life FcRn inhibitor BLA = Biologics License Application, Fc = fragment crystallizable, FcRn= neonatal Fc receptor, HV = healthy volunteer, IGF-1R = insulin-like growth factor-1 receptor, IND = Investigational New Drug, TED = thyroid eye disease, YE = year-end, IgG = immunoglobulin G. 4 Differentiated pipeline: TED portfolio moving towards commercial and FcRn inhibitor portfolio continues to progress Demonstrated proof-of-concept IgG reduction in HVs IND submission planned YE 2025 Pivotal trials fully enrolled BLA submitted in October 2025
Page 5
Source: 1Viridian THRIVE & THRIVE-2 data on file. BLA = Biologics License Application, FcRn = neonatal Fc receptor, IND = Investigational New Drug, IV = intravenous, MAA = Marketing Authorization Application, TED = thyroid eye disease, LDL = low-density lipoprotein, IgG = Immunoglobulin G. 5 Viridian is well-positioned to deliver significant catalysts Veligrotug Intravenous • Positive THRIVE and THRIVE-2 topline data in active and chronic TED showed a robust clinical profile1 • Strong durability of proptosis response in THRIVE • Breakthrough Therapy Designation granted May 2025 • Believe veligrotug is well-positioned to become the IV treatment-of-choice in TED BLA submission: October 2025 EU MAA submission: Q1 2026 U.S. launch, if approved under Priority Review timeline: Mid-2026 VRDN-003 Subcutaneous • REVEAL-1 and REVEAL-2 fully enrolled REVEAL-1 topline data: Q1 2026 REVEAL-2 topline data: Q2 2026 BLA submission: Year-end 2026 FcRn Portfolio • VRDN-006 phase 1 demonstrated IgG reduction and spared albumin and LDL Healthy volunteer data: Q3 2025 • VRDN-008 on track for IND submission year-end 2025 IND submission: Year-end 2025 Healthy volunteer data: 2H 2026 Corporate / Financial • Completed a comprehensive set of financing transactions in October 2025, securing access to up to $889 million of potential capital across equity, royalty financing, and credit • $289M public equity offering • Royalty financing agreement with DRI for up to $300M • Amended Hercules Credit Facility for up to $300M • Exclusive license agreement with Kissei Pharmaceutical to develop and commercialize TED portfolio in Japan (July 2025) • Approximately $887.9M cash as of October 31, 2025 Anticipated Catalysts
Page 6
Continue to Advance and Expand Pipeline FcRn Portfolio, New Programs * Planned; ** If approved. BLA = Biologics License Application, Fc = fragment crystallizable, FcRn = neonatal Fc receptor, MAA = Marketing Authorization Application, TED = thyroid eye disease. 6 Viridian is building a leadership position in autoimmune disease 2026 2027+ BLA and MAA Submission & Commercial Readiness Commercial Transition Revenue-Funded Growth 2025 EU MAA Submission* BLA Submission Launch** Active & Chronic TED BLA Submission* Advance Potential Best-in-Class FcRn Portfolio Launch** Active & Chronic TED Veligrotug v VRDN-003 v
Page 7
7 Thyroid Eye Disease (TED) Portfolio
Page 8
Sources: 1 George A et al. Front Endocrinol (Lausanne). 2021;11:629925., 2 Smith TJ et al. NEJM. 2016;375(16):1552–1565., 3 Bahn RS. NEJM. 2010; 362(8): 726–738., 4 Bartley GB et al. Am J Ophthalmol 1996;121(3):284–290., 5 Viridian-sponsored market research, includes active and chronic TED. TED patient images are from Bahn RS. NEJM. 2010; 362(8): 726–738. Copyright © (2010) Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. IGF-1R = insulin-growth factor 1 receptor, TED = thyroid eye disease, TSHR = thyroid stimulating hormone receptor. 8 TED is an autoimmune condition characterized by inflammation, growth, and damage to tissues around and behind the eyes Normal Eye Anatomy Bulging Eyes Enlargement of extraocular muscles Optic Nerve Autoantibodies trigger IGF-1R/TSHR pathway1 Heterogeneous autoimmune disease with clinical signs and symptoms that can vary or modulate following onset, in some cases for the rest of a patient’s life2,3 Main signs include proptosis (eye bulging), redness, swelling, diplopia (double vision), and lid retraction2,3 Severe cases can cause sight-threatening optic nerve compression4 An estimated 190K people in the US alone have moderate to severe TED5 People living with TED experience proptosis, redness, swelling, diplopia, and lid retraction Thyroid Eye Disease (TED)
Page 9
Source: 1 Viridian THRIVE and THRIVE-2 data on file. BLA = Biologics License Application, IGF-1R = insulin-like growth factor-1 receptor, IV = intravenous, MAA = Marketing Authorization Application, Q4W = every 4 weeks, Q8W = every 8 weeks, TED = thyroid eye disease. 9 Viridian is developing an IGF-1R antibody portfolio with the potential to transform the treatment for people living with TED Veligrotug VRDN-003 Steroids/ Surgery Phase 3 clinical data shows a robust clinical profile1 in a new start TED market • Statistically significant and consistent clinical responses in active and chronic TED • Rapid onset of treatment effect • First demonstration of diplopia response and resolution in chronic TED • Strong durability of proptosis response in THRIVE • Generally well-tolerated • Significantly reduced treatment burden Subcutaneous and potential best-in-class therapy Q8W or Q4W dosing; self-administered autoinjector planned REVEAL-1 and REVEAL-2 on track for topline data in Q1 2026 and Q2 2026, respectively First approved targeted therapy for TED 8 IV infusions Teprotumumab
Page 10
y Primed for new entrants and growth • Large and growing market1 • Recent IGF-1R approvals in Japan, EU & UK will expand global market2,3,4,5 • No subcutaneous option available commercially Current TED Market ~$2B1 Annualized TED market Source: 1Annualized TEPEZZA sales based on Amgen Q4 2024 Earnings, 2 Amgen Press Release “TEPEZZA® (TEPROTUMUMAB) RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF ACTIVE THYROID EYE DISEASE,” 3 Amgen Press Release “AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY,” 4 Amgen Press Release “AMGEN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS,” 5 Amgen Press Release “Amgen’s TEPEZZA®▼ (teprotumumab) granted marketing authorisation as the first targeted treatment specifically for adults with moderate-to-severe Thyroid Eye Disease (TED) in the United Kingdom,” 6 Viridian THRIVE data on file, 7 Viridian THRIVE-2 data on file, 8 Planned product profile, including planned clinical dosing regimen. BLA = Biologics License Application, IGF-1R = insulin-like growth factor-1 receptor, IV = intravenous, TED = thyroid eye disease. 10 Positive THRIVE and THRIVE-2 results support the transformative potential of veligrotug and ongoing VRDN-003 development • Robust and consistent clinical responses in active and chronic TED6,7 • Rapid onset of treatment effect6,7 • First demonstration of diplopia response and resolution in a global chronic TED phase 3 study7 • Generally well-tolerated6,7 • Significantly reduced treatment burden6,7 • New-start market dynamic enables potential rapid uptake for new entrant Veligrotug v Well-positioned to become the IV treatment-of-choice in TED • Transformative convenience of at-home autoinjector every 4 or 8 weeks8 • Shares same binding domain as veligrotug • BLA submission anticipated in the year following veligrotug BLA • Potential to greatly expand TED market, if approved Subcutaneous and potential best-in-class therapy in TED VRDN-003
Page 11
11 Veligrotug Intravenous anti–IGF-1R
Page 12
CHRONIC TED Key Inclusion Criteria • Proptosis of ≥3 mm • Any CAS (0-7) • Onset of TED symptoms >15 months Trial Design • N = approx. 159 (actual enrollment: 188 patients) • 15-week primary endpoint, 52-week total follow-up • Double-masked, randomized, placebo-controlled ACTIVE TED Key Inclusion Criteria • Proptosis of ≥3 mm • CAS ≥3 • Onset of TED symptoms within 15 months Trial Design • N = 90 (actual enrollment: 113 patients) • 15-week primary endpoint, 52-week total follow-up • Double-masked, randomized, placebo-controlled 12 Source: Viridian THRIVE and THRIVE-2 data on file. CAS = clinical activity score, mm = millimeter, TED = thyroid eye disease. Veligrotug met all primary and secondary endpoints with statistical significance in two phase 3 trials, THRIVE and THRIVE-2 Topline results reported December 2024 Met all primary & secondary endpoints Topline results reported September 2024 Met all primary & secondary endpoints THRIVE and THRIVE-2 evaluated veligrotug in the broadest population of active and chronic TED patients to date
Page 13
Achieved all primary and secondary endpoints with high level of statistical significance (p < 0.0001) Source: Viridian THRIVE week 15 topline data on file (interim topline database lock) & week 52 data on file (final database lock). AE = adverse event, IGF-1R = insulin-like growth factor-1 receptor, SAE = serious adverse event, TED = thyroid eye disease. 13 THRIVE: Veligrotug showed robust and consistent clinical activity in active TED patients Rapid onset of treatment effect in as few as 3 weeks Generally well-tolerated, with no treatment-related SAEs and low (5.5%) placebo-adjusted rate of hearing impairment AEs at week 15; consistent safety profile through week 52 Demonstrated strong durability of proptosis response: 70% of topline proptosis responders maintained response at week 52 (Active TED) Detailed data can be found in appendix starting on slide 31
Page 14
Source: Viridian THRIVE-2 week 15 topline data on file (interim topline database lock). AE = adverse event, IGF-1R = insulin-like growth factor-1 receptor, TED = thyroid eye disease. 14 THRIVE-2: Demonstrated robust and consistent clinical activity in the largest and broadest TED phase 3 study completed to date Achieved all primary and secondary endpoints with statistical significance in largest IGF-1R antibody study in TED to date Rapid onset of treatment effect, with statistically significant proptosis response in as few as 3 weeks First pivotal phase 3 study to demonstrate statistically significant diplopia response & resolution in chronic TED Generally well-tolerated, with low (9.6%) placebo- adjusted rate of hearing impairment AEs (Chronic TED) Detailed data can be found in appendix starting on slide 41
Page 15
Sources: 1 Viridian THRIVE data on file, 2 Viridian THRIVE-2 data on file. AE = adverse event, BLA = Biologic License Application, CAS = clinical activity score, IV = intravenous, TED = thyroid eye disease. 15 Veligrotug is well-positioned to become the treatment-of-choice for active & chronic TED Active & chronic data in BLA submission Supported by one of the largest & broadest TED pivotal programs to date1,2 Generally well-tolerated Low rate of hearing impairment AEs1,2 Rapid onset of treatment effect Significant proptosis response demonstrated in as few as 3 weeks1,2 Significantly reduced treatment burden ~70% shorter infusion time and shorter course of therapy1,2 Robust clinical responses across all primary & secondary endpoints Consistent reductions in proptosis, diplopia, and CAS in both active & chronic TED1,2 Significant clinical activity on diplopia resolution & response First pivotal phase 3 study to demonstrate statistically significant impact on diplopia in chronic TED2
Page 16
• Narrow and well-defined call point supports small, efficient sales force • Estimated ~2,000 core prescribers in the U.S.6 • Tepro launched with field force of <100 sales reps7 • Established market price and reimbursement pathway • Current WAC price for tepro: ~$500K per complete treatment course in the U.S.8 • Established strong & deep KOL relationships • Investigators have experience with veligrotug, one of the largest TED clinical program to date 16 Sources: 1 Annualized teprotumumab sales based on Amgen Q4 2024 earnings, 2 Horizon 2Q 2020 and full-year 2020 earnings, 3 TEPEZZA® (teprotumumab-trbw) Patient Website, 4 Viridian-sponsored market research, includes active and chronic TED, 5 Viridian data on file, 6 Viridian internal claims analysis on file, 7 FiercePharma, “Horizon bulks up sales force ahead of $750M inflammatory eye drug launch,” published: June 25, 2019, 8 Internal estimate, based on 80 kg patient. KOL = key opinion leader, TED = thyroid eye disease, Tepro = teprotumumab, WAC = wholesale acquisition cost. Veligrotug’s robust clinical profile expected to drive rapid commercial adoption in TED, if approved Veligrotug is well-positioned to become the leading product in the new-start TED market • ~$2B single-product market in U.S.1 • Tepro launch as first entrant: $166M net sales in first full quarter of launch (2Q 2020), and $820M in launch year 2 • Only an estimated ~15k patients treated to date among estimated US prevalence of ~190K moderate to severe TED 3,4 • New-start market dynamic enables potential rapid uptake for new entrant • Strong patient demand for new options • >500 TED patients enrolled in Viridian clinical trials in 2025 to date5 • >400 TED patients enrolled in Viridian clinical trials in 2024 5 Large & Growing Market Focused Footprint
Page 17
17 Viridian’s launch preparation prioritizes thorough understanding of TED market and strong external stakeholder relationships Field Medical Leadership in place, >500 KOL and HCP engagements at October medical conferences Field Sales Leadership in place, actively staffing top launch-ready talent Market Access Leadership in place, actively engaging with payers Patient Services Leadership in place, infrastructure build underway Preparing for a mid-2026 Priority Review timeline Launch to focus on ~2,000 core prescribers, if approved Launch preparations are well underway with experienced leadership teams in place Viridian’s go-to-market approach built on a foundational understanding of the TED market driven by robust Physician, Patient, and Payer market research TED = thyroid eye disease, KOL = key opinion leader, HCP = healthcare provider
Page 18
18 VRDN-003 Subcutaneous half-life extended anti–IGF-1R
Page 19
TED = thyroid eye disease. 19 Positive phase 3 data for veligrotug in active and chronic TED support ongoing VRDN-003 development Veligrotug VRDN-003 Half-life extension technology Fully enrolled. Topline data release expected: REVEAL-1: Q1 2026; REVEAL-2 : Q2 2026 v THRIVE & REVEAL clinical programs share key features and operations Veligrotug & VRDN-003 share the same binding domain Robust and consistent clinical responses across active and chronic TED
Page 20
• Doubled market size after SC launch1 IV Drug SC Drug CD38 IV Launch: Nov 2015 by J&J for multiple myeloma SC Launch: May 2020 by J&J • 30% of new scripts converted in 3 years2 IV Drug SC Drug CD20 IV Launch: Mar 2017 by Roche for MS SC Launch: Aug 2020 by Novartis • Doubled combined CD20 market size after Kesimpta launch3,4 20 Third party trademarks used are the property of their respective owners. Sources: 1 https://www.fiercepharma.com/pharma/jjs-switch-iv-subcutaneous-darzalex-85-complete-us, 2. Novartis 2022 Q4 results, 3 Roche Earnings, 4 Novartis Q3 2023 Earnings. CD20 = cluster of differentiation 20 protein, CD38 = clusterof differentiation30 protein, IV = intravenous, IGF-1R = insulin-like growth factor-1 receptor, MS = multiple sclerosis, SC = subcutaneous. Later-entrant SC therapies have demonstrated ability to expand the market and take market share from incumbent IV Significant potential opportunity for a best-in-class, long half-life and convenient subcutaneous anti–IGF-1R IV to SC with same molecule IV to SC with new SC entrant • 85% of IV market converted in 2 years1
Page 21
21 Source: 1 Teprotumumab Prescribing Information, 2 Planned product profile, including planned clinical dosing regimen. IGF-1R = insulin-like growth factor-1 receptor,IV = intravenous, Q4W = every 4 weeks, Q8W = every 8 weeks, SC = subcutaneous. VRDN-003 designed to bring a potentially best-in-class therapy for patients Potential for reduced treatment burden to patients 6 SC Treatments Self-administered every 4 weeks 1 loading dose + 5 Q4W 3 SC Treatments Self-administered every 8 weeks + + 1 loading dose + 2 Q8W Easy self-administration transforms patient convenience Infrequent administration & low volume Flexibility for at-homeadministration Relieves infusion burden while potentially preserving anti–IGF-1R efficacy Lower drug exposure potentially improves safety Teprotumumab IV 1 8 INFUSIONS administered every 3 weeks VRDN-003 Autoinjector Phase 3 pivotal program is evaluating two dosing regimens: 60–90 min infusions = ~8–12 hours in an infusion chair + + + + + + + Potential VRDN-003 Benefits2 + + + + +
Page 22
Subcutaneous VRDN-003 Pharmacokinetic (PK) Modeling VRDN-003 development expected to proceed along its own clinical development path regarding dosing regimens and safety profile. PK modeling used a 2-compartment model, loading dose of 600 mg, and subsequent doses of 300 mg/doses at specified intervals for 24 weeks. Veligrotug PK modeling assumed 5 infusions, based on PK data from the two-infusion phase 2 TED study. Source: Viridian’s phase 2 multiple ascending dose study - clinical data and modeling on file. IV = intravenous, PK = pharmacokinetics, Q4W = every four weeks,Q8W = every eight weeks, SC = subcutaneous, TED = thyroid eye disease, wks = weeks. 22 PK model shows Q4W and Q8W dosing of VRDN-003 SC achieves predicted exposure levels of veligrotug at 3-10 mg/kg • Veligrotug exposures modeled from a phase 2 TED clinical trial inform the exposure ranges anticipated to produce clinical benefit – Two infusions of 3 and 10 mg/kg veligrotug IV, dosed three weeks apart, each showed robust clinical activity in a phase 2 TED clinical trial • Models of subcutaneous VRDN-003 Q4W and Q8W achieve the range of veligrotug exposures that showed robust clinical activity in a two- infusion phase 2 TED study – VRDN-003 and veligrotug have the same binding domain • Both proposed VRDN-003 dosing regimens – Q4W & Q8W – present potential for transformative options for TED patients 0 10 20 0 25 50 75 100 Concentration (μg/mL) 003 Q8W 24 wks 003 Q4W 24 wks 3 mg/kg IV exposure range (C min to Cavg) 10 mg/kg IV exposure range (Cmin to Cavg) weeks
Page 23
23 BLA = Biologics License Application, CAS = clinical activity score, mm = millimeter, TED = thyroid eye disease. Enrollment complete in ongoing phase 3 clinical trials for VRDN-003 REVEAL trials expected to deliver topline results in Q1 2026 and Q2 2026, respectively, to support anticipated BLA submission by year-end 2026 CHRONIC TED Key Inclusion Criteria • Proptosis of ≥3 mm • Any CAS (0–7) • Onset of TED symptoms >15 months Trial Design • N = 195 (actual enrollment: 204 patients) • 24-week primary endpoint, 52-week total follow-up • Double-masked, parallel-group, placebo-controlled ACTIVE TED Key Inclusion Criteria • Proptosis of ≥3 mm • CAS ≥3 • Onset of TED symptoms within 15 months Trial Design • N = 117 (actual enrollment: 132 patients) • 24-week primary endpoint, 52-week total follow-up • Double-masked, parallel-group, placebo-controlled Patients without response at 24 weeks may receive open-label VRDN-003
Page 24
1 600 mg loading dose given as two 300 mg injections. 2 Placebo injections administered at alternating study visits to maintain study blinding across arms. D = day, Q4W = every 4 weeks, Q8W = every 8 weeks, W = week. 24 REVEAL-1 & REVEAL-2 will evaluate Q4W and Q8W active arms of VRDN-003 versus placebo control Treatment Phase (20 weeks treatment with primary endpoint at 24 weeks) VRDN-003 Q4W1 D11 W4 W8 W12 W16 W20 VRDN-003 Q8W1,2 Placebo Key: VRDN-003 300 mg Placebo W24Treatment Arms (1:1:1) Through W52 Additional efficacy & safety follow-up through week 52 Primary efficacy endpoint: Proptosis responder rate Key secondary endpoints: • Proptosis change • Clinical Activity Score (CAS) • Diplopia (double vision) Primary Endpoint Analysis
Page 25
25 FcRn Inhibitor Portfolio
Page 26
Pathogenic autoantibodies cause inflammation and damage to healthy tissues and cells, driving the pathology of autoimmune diseases1 Serum levels of pathogenic autoantibodies are maintained, in part, by FcRn-mediated recycling1 FcRn inhibition reduces pathogenic autoantibody levels1, with demonstrated efficacy and safety in patients with gMG, CIDP, and ITP2 Source: 1 Pyzik M et al.Nat Rev Immunol. 2023;23:415–432, 2 Vyvgart Prescribing Information. CIDP = chronic inflammatory demyelinating polyneuropathy, FcRn = neonatal Fc receptor, gMG = generalized myasthenia gravis, IgG = immunoglobulin G, ITP = primary immune thrombocytopenia. 26 Pathogenic autoantibodies drive disease pathophysiology in a number of autoimmune diseases FcRn-Mediated Recycling of IgGs, Including Pathogenic Autoantibodies1 1 2 3 4 IgGs, including pathogenic autoantibodies, enter the cell1 IgGs and pathogenic autoantibodies bind to FcRns2 Unbound antibodies are degraded by the lysosome3 FcRn-bound IgGs, including pathogenic autoantibodies, are recycled4 IgG Degraded antibody FcRn Endosome Lysosome
Page 27
Source: 1 Pyzik M et al.Nat Rev Immunol. 2023;23:415–432. Fc = fragment crystallizable, FcRn = neonatal Fc receptor, IgG = immunoglobulin G. 27 Viridian’s portfolio of FcRn inhibitors aims to reduce circulating levels of pathogenic autoantibodies by blocking FcRn Fc fragment that blocks IgG from binding to FcRn Binds to albumin and FcRn for a more sustained reduction of pathogenic autoantibodies Fc fragment Fc fragment FcRn inhibitor and IgGs, including pathogenic autoantibodies, enter the cell1 FcRn inhibitor blocks IgGs from binding to FcRn2 Unbound IgGs, including pathogenic autoantibodies, are degraded by the lysosome, reducing serum levels3 The bound FcRn inhibitor and IgG are recycled and released4 1 2 3 4 VRDN-006 VRDN-008 Albumin binding domain Inhibition of FcRn Reduces IgGs, Including Pathogenic Autoantibodies1 FcRn Inhibitor IgG Degraded antibody FcRn Endosome Lysosome
Page 28
Projected WW MG and CIDP FcRn Market1 Source: 1 2024 actuals calculated from argenx (Vyvgart + Vyvgart Hytrulo), Zai Labs (Vyvgart), and UCB (Rystiggo) annual reported earnings; 2030 estimates based on Evaluate Pharma data for Vyvgart, Vyvgart Hytrulo, Rystiggo, Imaavy, batoclimab, and IMVT-1402, accessed July 2025. CIDP = chronic inflammatory demyelinating polyneuropathy, FcRn = neonatal Fc receptor, MG = myasthenia gravis, WW = worldwide. 28 FcRn inhibitors are a large market opportunity; market size of MG and CIDP alone are projected to be over $11B by 2030 ...with Potential in Additional Autoimmune Indications Sjogren’s Syndrome Lupus Nephritis Myositis Graves’ Disease 2024 2030 $11.2B $2.5B
Page 29
Fc = fragment crystallizable, FcRn = neonatal Fc receptor, FIH = first in human, IgG = immunoglobulin G, IND = Investigational New Drug, LDL = low-density lipoprotein, NHP = non-human primate, YE = year-end. 29 Viridian’s FcRn portfolio has the potential to capture significant market share in autoimmune indications VRDN-006 VRDN-008 v v IgG Suppression • IgG reduction data consistent with the FcRn inhibitor class • Deeper and more sustained reduction of IgG vs. efgartigimod in NHPs Dosing • Targeting patient self-administration in a convenient subcutaneous injection • Targeting a less frequent, self-administered, subcutaneous injection Safety • Spared albumin and LDL in healthy volunteers, generally well-tolerated • Expect to maintain the Fc fragment safety profile Half-life Extended Bispecific FcRn InhibitorHighly Selective Fc Fragment and FcRn Inhibitor
Page 30
Appendix 1) THRIVE in Active TED Pivotal Data 2) THRIVE-2 in Chronic TED Pivotal Data 3) VRDN-003 Phase 1 Data 4) FcRn Non-Human Primate Data 30
Page 31
31 THRIVE in Active TED Global phase 3 clinical trial pivotal data
Page 32
D = day, mm = millimeter, TED = thyroid eye disease, W = week. 32 THRIVE is a phase 3 randomized, controlled, double-masked trial of veligrotug in active TED Treatment Phase (12-week treatment period with primary endpoint at 15 weeks) Veligrotug n = 75 D1 W3 W6 W9 W12 Placebo n = 38 Key: Veligrotug 10 mg/kg Placebo W15Treatment Arms (2:1 randomization) Through W52 Additional efficacy & safety follow-up at: • Week 24 • Week 36 • Week 52 Primary efficacy endpoint: Proptosis responder rate Key secondary endpoints: • Proptosis mean change from baseline • Diplopia (double vision) • Clinical Activity Score (CAS) Primary Endpoint Analysis Final THRIVE readout at Week 52 Key Inclusion Criteria • CAS ≥3 • Onset of TED symptoms within 15 months • Proptosis of ≥3 mm
Page 33
7.8 Veligrotug (n = 75) Placebo (n = 38) Participant Demographics Age in years, mean (SD) 48.9 (12.4) 49.1 (12.5) Female sex, n (%) 56 (75%) 31 (82%) White race, n (%) 51 (68%) 19 (50%) Disease Characteristics Months since TED onset, mean (SD) 7.9 (3.7) 7.2 (3.8) Baseline proptosis by exophthalmometry (mm), mean (SD) 23.2 (3.1) 23.2 (3.3) Baseline CAS, mean (SD) 4.5 (1.0) 4.8 (1.1) Participants with diplopia, n (%) 50 (67%) 26 (68%) Diplopia (Gorman Score), mean (SD) 1 2.0 (0.8) 2.0 (0.7) Source: Viridian THRIVE week 15 topline data on file (interim topline database lock). Note: all proptosis & CAS reported values and endpoints in the data analysis are based on study eye (defined as eye with greater proptosis at baseline). 1 Of patients with diplopia at baseline. CAS = clinical activity score, mm = millimeter, SD = standard deviation, TED = thyroid eye disease. 33 THRIVE baseline characteristics were well-balanced between active and placebo arms
Page 34
Veligrotug (n=75) Placebo (n=38) p-value Proptosis Primary Endpoint: Proptosis responder rate (exophthalmometry)1 70% 5% p < 0.0001 Proptosis mean change from baseline (exophthalmometry) -2.89 mm -0.48 mm p < 0.0001 Diplopia Diplopia complete resolution2 54% 12% p < 0.0001 Diplopia responder rate3 63% 20% p < 0.0001 CAS Clinical activity score (CAS) 0 or 1 64% 18% p < 0.0001 CAS mean change from baseline -3.4 -1.7 p < 0.0001 Overall Response Overall responder rate (ORR)4 67% 5% p < 0.0001 Source: Viridian THRIVE week 15 topline data on file (interim topline database lock). 1 Percentage of participants with ≥2 mm reduction in proptosis from baseline in the study eye, without deterioration in the fellow eye (≥2 mm increase), 2 Percentage of participants with baseline diplopia (Gorman Score >0) and a score of 0 at Week 15, 3 Percentage of participants achieving a reduction of at least 1 on the Gorman subjective diplopia scale at week 15, among patients with diplopia at baseline, 4 Percentage of participants with ≥2 mm reduction in proptosis AND ≥2-point reduction in CAS from baseline in the study eye, without corresponding deterioration [≥2 mm/point increase] in proptosis or CAS in the fellow eye. CAS = clinical activity score. 34 THRIVE achieved high level of statistical significance across all primary and secondary endpoints at 15 weeks
Page 35
0 20 40 60 80 100 35 Source: Viridian THRIVE week 15 topline data on file (interim topline database lock). Results at time points before week 15 are from post-hoc analyses and are for descriptive purposes only. mm = millimeter, PBO = placebo. Primary endpoint of proptosis responder rate met at 15 weeks: 70% for patients receiving veligrotug compared with 5% on PBO 53% of patients receiving veligrotug achieved a proptosis response at 3 weeks, after just 1 infusion of veligrotug Proptosis Responder Rate Proptosis Mean Change from Baseline Proptosis Responder Rate (%)Baseline Week 3 Week 6 Week 9 Week 12 Week 15 -0.51 -0.67 -0.71 -0.72 -0.48 -1.82 -2.39 -2.66 -2.76 -2.89 -4 -3 -2 -1 0 Proptosis Mean Reduction (mm)Baseline Week 3 Week 6 Week 9 Week 12 Week 15 11% 53% 11% 64% 13% 64% 13% 72% 5% 70% Analysis Visits Placebo Veligrotug Analysis Visits Placebo Veligrotug
Page 36
0 20 40 60 80 100 0 20 40 60 80 100 Source: Viridian THRIVE week 15 topline data on file (interim topline database lock). Results at time points before week 15 are from post-hoc analyses and are for descriptive purposes only. CAS = clinical activity score. 36 Majority of patients receiving veligrotug had complete resolution of diplopia and minimal disease activity (CAS) at week 15 Diplopia Complete Resolution CAS Score 0 or 1 Analysis Visits Diplopia Resolution Rate (%) Baseline Week 3 Week 6 Week 9 Week 12 Week 15 Placebo Veligrotug 4% 26% 12% 32% 12% 35% 12% 44% 12% 54% Diplopia Responder Rate at Week 15 63% 20% Diplopia Responder Rate at Week 15 7% 30% 25% 46% 24% 53% 20% 64% 18% 64% Analysis Visits CAS 0 or 1 Rate (%) Baseline Week 3 Week 6 Week 9 Week 12 Week 15 Placebo Veligrotug
Page 37
Source: Viridian THRIVE week 15 topline data on file (interim topline database lock). CT = computed tomography, IGF-1R = insulin-like growth factor-1 receptor, mm = millimeter, MRI = magnetic resonance imaging. 37 THRIVE demonstrated consistency between Hertel and MRI / CT and validates both as reliable tools for measurements of proptosis Veligrotug (n=75) Placebo (n=38) Proptosis responder rate at week 15 70% 5% Proptosis mean change from baseline at week 15 -2.89 mm -0.48 mm Veligrotug (n=75) Placebo (n=38) Proptosis responder rate at week 15 69% 9% Proptosis mean change from baseline at week 15 -2.91 mm -0.58 mm Hertel Exophthalmometry MRI / CT
Page 38
Source: Viridian THRIVE week 15 topline data on file (interim topline database lock). 1 6 unrelated SAEs in 4 participants: cellulitis, appendicitis, dyspnoea, hyperthyroidism, aortic dissection (planned surgery for known Type B aortic dissection), depression (diagnosed prior to 1st dose); Includes multiple terms aggregated using standard sets of MedDRA terms. AE = adverse event, MedDRA= medical dictionary for regulatory activities, SAE = serious adverse event, TEAE = treatment-emergent adverse event. 38 Veligrotug was generally well-tolerated at week 15, with no treatment-related SAEs, and 96% of veligrotug-treated patients completed all doses Veligrotug N=75 n (%) Placebo N=38 n (%) Participants with any treatment-emergent adverse event (TEAE) 66 (88%) 24 (63%) Participants with any serious AE (SAE) 4 (5%)1 0 Participants with any treatment-related TEAE 53 (71%) 9 (24%) Participants with any treatment-related SAE 0 0 • Vast majority of TEAEs in both arms were mild • Low treatment discontinuation rate ‒ 4% in veligrotug arm • No treatment-related SAEs
Page 39
Source: Viridian THRIVE week 15 topline data on file (interim topline database lock). 1 Includes multiple terms aggregated using standard sets of MedDRA terms, 2 Reported as percentage of menstruating women. AE = adverse event, MedDRA = medical dictionary for regulatory activities. 39 Veligrotug was generally well-tolerated at week 15, with a 5.5% placebo-adjusted rate of hearing impairment AEs AEs occurring at ≥10% frequency in either arm Veligrotug N=75 n (%) Placebo N=38 n (%) Muscle spasms 32 (43%) 2 (5%) Headache 16 (21%) 5 (13%) Infusion related reaction (IRR) 13 (17%) 1 (3%) Hearing impairment1 12 (16%) 4 (11%) Hyperglycemia1 11 (15%) 2 (5%) Fatigue1 10 (13%) 6 (16%) Nausea 10 (13%) 3 (8%) Ear discomfort 9 (12%) 1 (3%) Diarrhea 8 (11%) 1 (3%) Alopecia 6 (8%) 4 (11%) Menstrual disorders1,2 8 / 34 (24%) 1 / 12 (8%)
Page 40
Source: Viridian THRIVE week 52 data on file (final database lock). 1 Responders at week 15 who still had at least a 2-millimeter (mm) reduction in proptosis compared to baseline at week 52, without worsening in the fellow eye (≥2 mm increase), as measured by exophthalmometry. Definition of durability is the same as that used for teprotumumab durability as reported in its U.S. Prescribing Information. • No changes to veli’s safety profile during the follow-up period • Vast majority of adverse events reported at topline resolved by Week 52 40 70% of proptosis responders in THRIVE maintained response at Week 52 in long-term follow up Proptosis Durability 70% (21/30 participants) of Week 15 proptosis responders maintained a proptosis response at Week 52 1 Safety Resolution
Page 41
41 THRIVE-2 in Chronic TED Global phase 3 clinical trial pivotal data
Page 42
D = day, mm = millimeter, TED = thyroid eye disease, W = week. 42 THRIVE-2 is a phase 3 randomized, controlled, double-masked trial of veligrotug in chronic TED Treatment Phase (12-week treatment period with primary endpoint at 15 weeks) Veligrotug n = 125 D1 W3 W6 W9 W12 Placebo n = 63 Key: Veligrotug 10 mg/kg Placebo W15Treatment Arms (2:1 randomization) Through W52 Additional efficacy & safety follow-up at: • Week 24 • Week 36 • Week 52 Primary efficacy endpoint: Proptosis responder rate Key secondary endpoints: • Proptosis mean change from baseline • Diplopia (double vision) • Clinical Activity Score (CAS) Primary Endpoint Analysis Final THRIVE-2 readout at Week 52 Key Inclusion Criteria • Any CAS (0–7) • Onset of TED symptoms >15 months • Proptosis of ≥3 mm
Page 43
Source: Viridian THRIVE-2 week 15 topline data on file (interim topline database lock). Note: all proptosis & CAS reported values and endpoints in the data analysis are based on study eye (defined as eye with greater proptosis at baseline). 1 Of participants with diplopia at baseline. CAS = clinical activity score, mm = millimeter, SD = standard deviation, TED = thyroid eye disease. 43 THRIVE-2 baseline characteristics were well-balanced between active and placebo arms Veligrotug (n = 125) Placebo (n = 63) Participant Demographics Age in years, mean (SD) 50.5 (13.5) 50.7 (12.0) Female sex, n (%) 95 (76%) 46 (73%) White race, n (%) 94 (75%) 48 (76%) Disease Characteristics Months since TED onset, mean (SD) 69.8 (78.9) 81.7 (83.7) Baseline proptosis by exophthalmometry (mm), mean (SD) 24.3 (3.3) 23.8 (3.3) Baseline CAS, mean (SD) 2.7 (1.9) 2.5 (1.8) Baseline CAS 0 or 1, n (%) 44 (35%) 22 (35%) Baseline CAS ≥ 3, n (%) 71 (57%) 33 (52%) Participants with diplopia, n (%) 65 (52%) 37 (59%) Diplopia (Gorman Score), mean (SD) 1 2.0 (0.8) 2.1 (0.9)
Page 44
Source: Viridian THRIVE-2 week 15 topline data on file (interim topline database lock). 1 Percentage of participants with ≥2 mm reduction in proptosis from baseline in the study eye, without deterioration in the fellow eye (≥2 mm increase), 2 Percentage of participants achieving a reduction of at least 1 on the Gorman subjective diplopia scale, among patients with diplopia at baseline (n=102 participants), 3 Percentage of participants with baseline diplopia (Gorman Score >0; n=102 participants) and a score of 0 at the analysis timepoint, 4 Percentage of participants with ≥2 mm reduction in proptosis AND no worsening in CAS from baseline in the study eye, without corresponding deterioration (≥2 mm/point increase) in proptosis or CAS in the fellow eye, 5 Of participants with CAS ≥3 at baseline (n=104 participants); CAS subpopulation analyses were prespecified, exploratory endpoints and statistical p values are for descriptive purposes only. CAS = clinical activity score. 44 THRIVE-2 met all primary and secondary endpoints at 15 weeks Veligrotug (n=125) Placebo (n=63) p-value Proptosis Primary Endpoint: Proptosis responder rate (exophthalmometry)1 56% 8% p < 0.0001 Proptosis mean change from baseline (exophthalmometry) -2.34 mm -0.46 mm p < 0.0001 Diplopia Diplopia responder rate2 56% 25% p = 0.0006 Diplopia complete resolution3 32% 14% p = 0.0152 Overall Response Overall responder rate (ORR)4 56% 7% p < 0.0001 CAS5 (prespecified exploratory endpoints) Clinical activity score (CAS) reduction to 0 or 15 54% 24% p = 0.0060 CAS mean change from baseline5 -2.9 -1.3 p < 0.0001
Page 45
-0.62 -0.72 -0.69 -0.75 -0.46 -1.06 -1.70 -2.04 -2.22 -2.34 -3 -2 -1 0 0 20 40 60 80 100 45 Source: Viridian THRIVE-2 week 15 topline data on file (interim topline database lock). Results at time points before week 15 are from prespecified, exploratory endpoint analyses. Statistically significant proptosis responder rate at all time points, including at 3 weeks, after just one infusion of veligrotug Rapid and statistically significant proptosis responder rate at 3 weeks, after just 1 infusion of veligrotug Proptosis Responder Rate Proptosis Mean Change from Baseline Proptosis Responder Rate (%)Baseline Week 3 Week 6 Week 9 Week 12 Week 15 Proptosis Mean Reduction (mm)Baseline Week 3 Week 6 Week 9 Week 12 Week 15 Analysis Visits Placebo Veligrotug Analysis Visits Placebo Veligrotug 10% 25% 13% 40% 11% 50% 13% 54% 8% 56%
Page 46
0 20 40 60 80 100 0 20 40 60 80 100 Source: Viridian THRIVE-2 week 15 topline data on file (interim topline database lock). Results at time points before week 15 are from prespecified, exploratory endpoint analyses. TED = thyroid eye disease. 46 THRIVE-2 is the first phase 3 study in patients with chronic TED to demonstrate statistically significant diplopia response & resolution Diplopia Responder Rate Diplopia Complete Resolution Diplopia Responder Rate (%) Baseline Week 3 Week 6 Week 9 Week 12 Week 15 Analysis Visits Placebo Veligrotug Diplopia Resolution Rate (%) Baseline Week 3 Week 6 Week 9 Week 12 Week 15 Analysis Visits Placebo Veligrotug 22% 29% 14% 47% 24% 52% 19% 55% 25% 56% 14% 18% 5% 31% 11% 36% 11% 33% 14% 32%
Page 47
47 Source: Viridian THRIVE-2 week 15 topline data on file (interim topline database lock). Study eye is defined as eye with greater proptosis at baseline, as measured by corresponding measurement modality (i.e., Hertel study eye for Hertel endpoints, and MRI / CT study eye for MRI / CT endpoints). CT = computed tomography, mm = millimeter, MRI = magnetic resonance imaging. THRIVE-2 demonstrated consistency between Hertel exophthalmometry and MRI / CT as measurements of proptosis THRIVE-2 demonstrated both exophthalmometry and MRI / CT are reliable tools for measurement of proptosis, building on data from THRIVE Hertel exophthalmometry MRI / CT Veligrotug (n=125) Placebo (n=63) Proptosis responder rate at week 15 56% 8% Proptosis mean change from baseline at week 15 -2.34 mm -0.46 mm Veligrotug (n=125) Placebo (n=63) Proptosis responder rate at week 15 48% 3% Proptosis mean change from baseline at week 15 -2.07 mm -0.36 mm
Page 48
Source: Viridian THRIVE-2 week 15 topline data on file (interim topline database lock). 1 3 SAEs in 3 participants: Grade 3 vertigo (related), Grade 2 arthralgia (unrelated), Grade 2 metabolic encephalopathy (unrelated); 2 2 SAEs in 2 participants: Grade 3 urticaria (related), Grade 3 fatigue (unrelated). AE = adverse event, SAE = serious adverse event, TEAE = treatment-emergent adverse event. 48 Veligrotug was generally well-tolerated, and 94% of veligrotug-treated patients completed their treatment course Veligrotug N=125 n (%) Placebo N=63 n (%) Participants with any treatment-emergent adverse event (TEAE) 106 (85%) 43 (68%) Participants with any serious AE (SAE) 3 (2%)1 2 (3%)2 Participants with any treatment-related TEAE 79 (63%) 14 (22%) Participants with any treatment-related SAE 1 (1%)1 1 (2%)2 • Vast majority of TEAEs in both arms were mild • Low treatment discontinuation rate ‒ 6% in veligrotug arm
Page 49
Source: Viridian THRIVE-2 week 15 topline data on file (interim topline database lock). 1 Terms aggregated utilizing methodology used by FDA for approved products for treatment of thyroid eye disease, 2 Reported as percentage of menstruating women. AE = adverse event. 49 Veligrotug was generally well-tolerated, with a 9.6% placebo-adjusted rate of hearing impairment AEs AEs occurring at ≥10% frequency in either arm Veligrotug N=125 n (%) Placebo N=63 n (%) Muscle spasms 45 (36%) 4 (6%) Headache 18 (14%) 8 (13%) Hearing impairment1 16 (13%) 2 (3%) Fatigue1 15 (12%) 5 (8%) Diarrhea 14 (11%) 6 (10%) Hyperglycaemia1 13 (10%) 3 (5%) Menstrual Disorders1,2 16 / 48 (33%) 2 / 20 (10%)
Page 50
50 VRDN-003 Phase 1 Data
Page 51
Source: Preliminary Viridian clinical data on file as of April 12, 2024 data cut. Multi-dose cohort was a 600 mg loading dose followed by a 300 mg second dose at day 28. Six participants were dosed in each of the single-dose VRDN-003 cohorts, and four participants were dosed in the multi-dose cohort. IGF-1 = insulin-like growth factor 1, HV = healthy volunteers, PD = pharmacodynamics, PK = pharmacokinetics, SC = subcutaneous. 51 Phase 1 HV Study: Subcutaneous VRDN-003 showed an extended half-life of 40–50 days and sustained IGF-1 levels after dosing VRDN-003 half-life is 40–50 days VRDN-003 increases IGF-1 levels ~4-fold 0 50 100 150 0.1 1 10 100 Time (Days) Drug Concentration (μg/mL) VRDN-003 SC (300 mg single dose) VRDN-003 SC (600 mg single dose) VRDN-003 SC (600 mg + 300 mg multi-dose) 0 50 100 150 0 2 4 6 Time (Days) Fold Change from Baseline IGF-1 VRDN-003 SC (300 mg single dose) Placebo VRDN-003 SC (600 mg single dose) VRDN-003 SC (600 mg + 300 mg multi-dose) PK / PD updated with multi-dose cohort Phase 1 HV Pharmacokinetics (PK) Phase 1 HV Pharmacodynamics (PD)
Page 52
• No hearing-related AEs • No treatment-related discontinuations • All VRDN-003 related AEs were Grade 1 (mild), no SAEs • All treatment-related AEs resolved during follow-up 1 Injection Site Reactions and Hearing Impairment each includes multiple MedDRA terms. Source: Preliminary Viridian clinical data on file as of April 12, 2024 data cut. ADA = anti-drug antibodies, AE = adverse event, HV = healthy volunteer, ISRs = Injection Site Reaction, MedDRA = Medical Dictionary for Regulatory Activities, SAE = serious adverse event, SC = subcutaneous. 52 Phase 1 HV Study: Subcutaneous VRDN-003 was well-tolerated VRDN-003 Single Dose SC (n = 12) Two Doses SC (n = 4) Placebo (n = 6) All Observed AEs 9 (n = 3) 2 (n = 2) 2 (n = 2) AEs deemed to be related to VRDN-003 3 1 -- Injection Site Reactions (ISRs)1 1 (8%) -- -- Muscle Spasms -- -- -- Hyperglycemia -- 1 (25%) -- Hearing Impairment1 -- -- -- Insomnia 1 (8%) -- -- Hepatic Enzyme Increase 1 (8%) -- -- Severe Adverse Events (SAEs) -- -- 1 (16.7%) # Grade 3/4 AEs -- -- 1 (16.7%) # Anti-Drug Antibodies (ADAs) Low ADAs detected after Day 71 # One participant in the placebo arm was diagnosed with stage 4 lung cancer, which was considered both a SAE and a Grade 3/4 AE. The participant subsequently withdrew from the study.
Page 53
53 FcRn Non-Human Primate Data
Page 54
Non-human primates (NHPs) were dosed with IV bolus of 20 mg/kg VRDN-006, 20 mg/kg efgartigimod (internally generated benchmark), or buffer vehicle every 4 days for 4 doses. Source: Viridian data on file. IgG = Immunoglobulin G, IV = intravenous, NHP = non-human primate, PK= pharmacokinetics, WT Fc = wild type neonatal fragment. 54 VRDN-006 in vitro, multi-dose NHP PK and IgG reduction data compared to efgartigimod pH-Dependent Binding Internal Target Occupancy 0.01 0.1 1 10 100 1000 10000 0 1×106 2×106 3×106 Concentration (nM) Mean Flourescence Intensity Efgartigimod WT Fc Control VRDN-006 0.0001 0.001 0.01 0.1 1 10 100 1000 0 1×105 2×105 3×105 4×105 Concentration (nM) Mean Flourescence Intensity WT Fc Control Efgartigimod VRDN-006 pH 7.4 pH 6 Multi-Dose NHP Pharmacokinetics 0 5 10 15 20 25 1 10 100 1000 Time (Days) Serum Concentration [μg/mL] VRDN-006 (20 mg/kg, IV) Efgartigimod (20 mg/kg, IV) Dose 0 5 10 15 20 25 0 50 100 150 Time (Days) IgG Response (%) Efgartigimod (20 mg/kg, IV) VRDN-006 (20 mg/kg, IV) Vehicle Dose v Multi-Dose NHP Pharmacodynamics
Page 55
VRDN-006 Spares Albumin VRDN-006 Spares LDL Non-human primates (NHPs) were dosed with IV bolus of 20 mg/kg VRDN-006, 20 mg/kg efgartigimod (internally generated benchmark), or buffer vehicle every 4 days for 4 doses. Source: Viridian data on file. CFB = change from baseline, IV = intravenous, LDL = low-density lipoprotein, NHP = non-human primate. 55 VRDN-006 spares albumin and LDL in multi-dose NHP study 0 5 10 15 20 25 0 50 100 150 200 Time (Days) CFB Concentrations (%)Vehicle Efgartigimod (20 mg/kg, IV) VRDN-006 (20 mg/kg, IV) Dose 0 5 10 15 20 25 0 50 100 150 Time (Days) CFB Concentrations (%) Vehicle Efgartigimod (20 mg/kg, IV) VRDN-006 (20 mg/kg, IV) Dose v
Page 56
VRDN-008 Showed ~3x Longer Half-life Head-to-Head vs. Efgartigimod in NHPs VRDN-008 Showed ~20% Deeper and More Sustained IgG Reduction Head-to-Head vs. Efgartigimod in NHPs v Non-human primates (NHPs) were given equimolar doses of 60 mg/kg VRDN-008, 48.5 mg/kg efgartigimod (internally generated benchmark), or buffer vehicle - all via IV bolus. Source: Viridian data on file. BLQ = below limit of quantification, IgG = Immunoglobulin G, IV = intravenous, NHP = non-human primate. 56 A single dose of VRDN-008 demonstrated a longer half-life, deeper and more sustained reduction of IgG vs. efgartigimod 0 7 14 21 28 35 42 0.01 1 100 10000 Time (Days) Concentration (μg/ml) VRDN-008 (60 mg/kg, IV) Efgartigimod (48.5 mg/kg, IV) 0 7 14 21 28 35 42 0 25 50 75 100 125 150 Time (Days) IgG Concentration Mean % Change from Baseline VRDN-008 (60 mg/kg, IV) Efgartigimod (48.5 mg/kg, IV) Vehicle Efgartigimod levels were BLQ at Weeks 35 and 42
Page 57
VRDN-008 Spares Albumin VRDN-008 Spares LDL 0 7 14 21 28 35 42 50 75 100 125 Time (Days) Albumin Concentration Mean % Change from Baseline VRDN-008 (60 mg/kg, IV) Efgartigimod (48.5 mg/kg, IV) Vehicle 0 7 14 21 28 35 42 50 100 150 Time (Days) LDL Concentration Mean % Change from Baseline VRDN-008 (60 mg/kg, IV) Efgartigimod (48.5 mg/kg, IV) Vehicle Non-human primates (NHPs) were given equimolar doses of 60 mg/kg VRDN-008, 48.5 mg/kg efgartigimod (internally generated benchmark), or buffer vehicle - all via IV bolus. Source: Viridian data on file. IV = intravenous, LDL = low-density lipoprotein, NHPs = non-human primates. 57 A single dose of VRDN-008 spares albumin and LDL in NHPs v